What Arecor does
Arecor Limited is a privately-owned biopharmaceuticals company developing superior diabetes care through the application of its innovative formulation technology platform.
Arecor is leveraging this platform to:
(i) develop a portfolio of proprietary products for diabetes care
(ii) deliver superior reformulations of its partners proprietary products.
It partners with major pharma and biotech companies to develop improved versions of their key products, as well as developing its own products.
In February, the firm inked a further collaboration agreement with a top five pharmaceutical company to develop a liquid formulation of a ready-to-administer (RTA) medicine using its Arestat technology.
The biopharma group said its partner will fund a feasibility study into the formula and will retain an exclusive option to a global royalty bearing licence for the product and Arecor’s associated IP.
In January, Arecor also signed an agreement with FTSE 100 firm Hikma Pharmaceuticals PLC (LON:HIK) to develop a new, ready-to-use injectable medicine.
The new product, to be announced prior to launch, will use Arecor’s Arestat drug formulation technology and is expected to be submitted to the US Food and Drug Administration for regulatory approval in 2021.
In December, Arecor hailed the successful completion of a phase I trial for its ultra-rapid acting insulin for diabetics, which it said had a “favourable profile” when compared with standard treatments.
The company said that its candidate, AT247, had finished a phase I double-blind, randomised study at The Medical University of Graz and Joanneum Research in Austria, in which it was measured against two other insulins on the market, NovoRapid and Fiasp.
Watch the interview
What the boss says
Sarah Howell, chief executive, called the completion of the phse 1 study “an important step” for the company’s goal to improve treatment and healthcare outcomes for people living with Type I diabetes.
“With AT247’s favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape,” Howell said, noting that full data from the phase I study will be reported “in due course”.